Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Florent Grange

Showing results (61-70 of 80) with videos related to

Pageof 8
Sort By:
The Lancet. Oncology|October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.
The New England Journal of Medicine|November 18, 2014
Improved overall survival in melanoma with combined dabrafenib and trametinibCaroline Robert, Boguslawa Karaszewska, Jacob Schachter, et al.
Histopathology|December 4, 2024
Recurrent primary cutaneous marginal zone lymphoma: a comparative study of initial tumours, recurrences, and outcomes in 61 patientsFanny Beltzung, Marie Beylot-Barry, Maxime Battistella, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
Journal of Cutaneous Pathology|November 19, 2005
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspectsGünter Burg, Werner Kempf, Antonio Cozzio, et al.
The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
The British Journal of Dermatology|July 14, 2025
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL)Charlée Nardin, Charlotte Cavalieri, Céleste Lebbé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2022
Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell CarcinomaAndrey A Yurchenko, Oltin T Pop, Meriem Ighilahriz, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2026
Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCACaroline Robert, Emilie Gérard, Emilie Lanoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2020
Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell CarcinomasEve Maubec, Marouane Boubaya, Peter Petrow, et al.
Pageof 8

Showing results (61-70 of 80) with videos related to

Sort By:
Pageof 8
The Lancet. Oncology|October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.
The New England Journal of Medicine|November 18, 2014
Improved overall survival in melanoma with combined dabrafenib and trametinibCaroline Robert, Boguslawa Karaszewska, Jacob Schachter, et al.
Histopathology|December 4, 2024
Recurrent primary cutaneous marginal zone lymphoma: a comparative study of initial tumours, recurrences, and outcomes in 61 patientsFanny Beltzung, Marie Beylot-Barry, Maxime Battistella, et al.
Journal for Immunotherapy of Cancer|June 7, 2020
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanomaPaolo Antonio Ascierto, Michele Del Vecchio, Andrzej Mackiewicz, et al.
Journal of Cutaneous Pathology|November 19, 2005
WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspectsGünter Burg, Werner Kempf, Antonio Cozzio, et al.
The Lancet. Oncology|April 1, 2017
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trialPaolo A Ascierto, Michele Del Vecchio, Caroline Robert, et al.
The British Journal of Dermatology|July 14, 2025
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL)Charlée Nardin, Charlotte Cavalieri, Céleste Lebbé, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2022
Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell CarcinomaAndrey A Yurchenko, Oltin T Pop, Meriem Ighilahriz, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2026
Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCACaroline Robert, Emilie Gérard, Emilie Lanoy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 31, 2020
Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell CarcinomasEve Maubec, Marouane Boubaya, Peter Petrow, et al.
Pageof 8